Who Paid My Doc
Uplizna
Drug Uplizna
NDC 72677-551-01
General payments
$9,505,807
Research payments
$4,052,081
Through program year 2023, $9,505,807 in general payments and $4,052,081 in research payments were reported against Uplizna (Uplizna).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
6 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | General | $4,605,696 | 10,079 |
| 2023 | Research | $936,302 | 27 |
| 2022 | General | $3,391,000 | 10,110 |
| 2022 | Research | $1,909,532 | 23 |
| 2021 | General | $1,509,111 | 3,269 |
| 2021 | Research | $1,206,247 | 22 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2023.
The top 5 of 82 specialties; each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.
The top 5 of 51 states; each share is of general payments naming this product in 2023 where a state was reported.
Records
23,458 general · 72 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.